Baotou Dongbao Bio-Tech Co.,Ltd Stock

Equities

300239

CNE100001583

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
4.73 CNY -0.84% Intraday chart for Baotou Dongbao Bio-Tech Co.,Ltd -7.25% -24.08%
Sales 2021 612M 84.56M Sales 2022 943M 130M Capitalization 4.45B 615M
Net income 2021 36M 4.97M Net income 2022 109M 15.06M EV / Sales 2021 6.55 x
Net cash position 2021 175M 24.22M Net cash position 2022 161M 22.24M EV / Sales 2022 4.55 x
P/E ratio 2021
109 x
P/E ratio 2022
40.7 x
Employees 1,356
Yield 2021
0.09%
Yield 2022
0.35%
Free-Float 31.46%
More Fundamentals * Assessed data
Dynamic Chart
Baotou Dongbao Bio-Tech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Baotou Dongbao Bio-Tech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Baotou Dongbao Bio-Tech Raises 455 Million Yuan From Bond Sale MT
Baotou Dongbao Bio-Tech Co.,Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 19 May 2023 CI
Baotou Dongbao Bio-Tech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Baotou Dongbao Bio-Tech Co.,Ltd Approves Cash Dividend for the Year 2022 CI
Baotou Dongbao Bio-Tech Co.,Ltd Proposes Cash Dividend for 2022 CI
Baotou Dongbao Bio-Tech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Baotou Dongbao Bio-Tech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Qingdao Yiqing Biotechnology Co., Ltd. announced that it has received CNY 100.45 million in funding from Baotou Dongbao Bio-Tech Co.,Ltd, Qingdao Gon Technology Co., Ltd., Qingdao Deyu Biological Investment Partnership (limited partnership) CI
Baotou Dongbao Bio-Tech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Qingdao Yiqing Biotechnology Co., Ltd. announced that it expects to receive CNY 100.45 million in funding from Baotou Dongbao Bio-Tech Co.,Ltd, Qingdao Gon Technology Co., Ltd., Qingdao Deyu Biological Investment Partnership (limited partnership) CI
Baotou Dongbao Bio-Tech Co.,Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 10 June 2022 CI
Baotou Dongbao Bio-Tech Co.,Ltd Approves Profit Distribution Plan for 2021 CI
Baotou Dongbao Bio-Tech Co.,Ltd Proposes Cash Dividend for 2021 CI
More news
1 day-0.84%
1 week-7.25%
Current month-7.98%
1 month-8.33%
3 months-16.28%
6 months-21.69%
Current year-24.08%
More quotes
1 week
4.59
Extreme 4.59
5.18
1 month
4.59
Extreme 4.59
5.43
Current year
3.63
Extreme 3.63
6.40
1 year
3.63
Extreme 3.63
6.80
3 years
3.63
Extreme 3.63
9.39
5 years
3.63
Extreme 3.63
9.85
10 years
3.39
Extreme 3.39
14.68
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 21-09-09
Director of Finance/CFO 48 19-04-16
Director/Board Member 37 21-09-09
Members of the board TitleAgeSince
Chairman 55 21-09-09
Director/Board Member 69 20-05-11
Chief Executive Officer 60 21-09-09
More insiders
Date Price Change Volume
24-04-19 4.73 -0.84% 3,922,827
24-04-18 4.77 -0.63% 5,224,900
24-04-17 4.8 +4.58% 7,964,029
24-04-16 4.59 -5.56% 8,599,529
24-04-15 4.86 -4.71% 11,074,920

End-of-day quote Shenzhen S.E., April 18, 2024

More quotes
Baotou Dongbao Bio-Tech Co., Ltd is principally engaged in the research, development, manufacture and distribution of gelatin series products and low molecular mass collagen. The Company primarily provides gelatin, which is used in the manufacture of empty capsules and food additives; calcium hydrophosphate, which is used in feed additives, as well as collagen series products, which are used in foods, cosmetics, health care products. The Company distributes its products in both domestic and overseas markets, with domestic markets as its major markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 300239 Stock